Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.54 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | VNN1 | O95497 | 4/20 | 0.53 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438988 | 1.00 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2TTRVNN1 | |
| SCHEMBL10659911 | 0.86 | VNN1 (0.56) | TAS1R3TAS1R1TAS1R2VNN1KCNQ3 | |
| SCHEMBL14825526 | 0.85 | LMNA (0.47) | TAS1R3TAS1R1TAS1R2TTRVNN1 | |
| SCHEMBL17352126 | 0.85 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2TTRVNN1 | |
| SCHEMBL31401262 | 0.85 | LMNA (0.47) | TAS1R3TAS1R1TAS1R2TTRVNN1 | |
| SCHEMBL17352124 | 0.85 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2TTRVNN1 | |
| SCHEMBL26090159 | 0.85 | LMNA (0.47) | TAS1R3TAS1R1TAS1R2TTRVNN1 | |
| SCHEMBL29620952 | 0.84 | KIF11 (0.57) | TTRKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL850429 | 0.84 | KIF11 (0.57) | TTRKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL31319449 | 0.83 | RXRA (0.48) | TTRRXRARXRBRXRGSRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240011009-A1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230220589-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2023-07-13 | — | — | US | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| US-20170098787-A1 | MAIN GROUP METAL COMPLEXES AS P-DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | SIEMENS AKTIENGESELLSCHAFT (DE) | 2017-04-06 | — | — | US | claimed |
| EP-3114715-A1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | Siemens Aktiengesellschaft (DE) | 2017-01-11 | — | — | EP | claimed |
| EP-3057151-A1 | PRINCIPAL GROUP METAL COMPLEXES AS P DOTANDS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | Siemens Aktiengesellschaft (DE) | 2016-08-17 | — | — | EP | claimed |
| US-9040268-B2 | Method for controlling undesirable byproducts formation caused by contaminating organisms in the production of ethanol from syngas | COSKATA, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-8853619-B2 | Method for detecting tracer compounds for hydrocarbon production | TOTAL S.A. (FR) | 2014-10-07 | — | — | US | claimed |
| EP-2758540-A1 | METHOD FOR CONTROLLING UNDESIRABLE BYPRODUCTS FORMATION CAUSED BY CONTAMINATING ORGANISMS IN THE PRODUCTION OF ETHANOL FROM SYNGAS | Coskata Energy Inc. (US) | 2014-07-30 | — | — | EP | claimed |
| CN-103958690-A | Method for controlling undesirable byproducts formation caused by contaminating organisms in the production of ethanol from syngas | COSKATA INC | 2014-07-30 | — | — | CN | claimed |
| WO-2013043513-A1 | METHOD FOR CONTROLLING UNDESIRABLE BYPRODUCTS FORMATION CAUSED BY CONTAMINATING ORGANISMS IN THE PRODUCTION OF ETHANOL FROM SYNGAS | COSKATA, INC. (US) | 2013-03-28 | — | — | WO | claimed |
| US-20130071897-A1 | METHOD FOR CONTROLLING UNDESIRABLE BYPRODUCTS FORMATION CAUSED BY CONTAMINATING ORGANISMS IN THE PRODUCTION OF ETHANOL FROM SYNGAS | COSKATA, INC. (US) | 2013-03-21 | — | — | US | claimed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170098787-A1 | MAIN GROUP METAL COMPLEXES AS P-DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | SCO2, SOD3, NCOA3 | TAS1R3 3359/4885TAS1R1 3965/4885TAS1R2 3871/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | TAS1R3 850/4885TAS1R1 521/4885TAS1R2 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.